Lupus & antiphospholipid syndrome
Subsets of Patients With Lupus Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib
Authors' conclusion
Transcriptomic analysis identified subsets of patients with SLE responsive to baricitinib.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) enrolled in the phase 2 baricitinib trial; whole-blood samples8 endotypes (A-H)
- Participants
- 272 patients
- Comparison
- Baricitinib vs placebo, by molecular endotype
Methodological detailstranscriptomic analysis, baseline and longitudinal, Gene Set Variation Analysis (GSVA) of 32 immune-related gene modules
- Transcriptomic analysis
- Baseline and longitudinal
- GSVA of 32 immune-related gene modules
Primary result
As reported in the abstract
SRI-4 response, baricitinib vs placebo, by endotype · 24 weeks
Effect size (endotype D)
41.54%
P = 0.004
endotype D
Effect size (endotype G)
31.89%
0.048
endotype G
Further findings
Treatment-related transcriptional modulation (endotype G) · week 2 to week 24
- Dose-dependent suppression of interferon, JAK1/JAK2/TYK2 signaling, immunoproteasome and inflammatory pathways, from week 2, sustained through week 24
- Transcriptional changes largely confined to clinical responders in endotype G
Predictors of response (feature importance analysis)
- Interferon and Treg cell signatures were major predictors of response
Baseline characteristics across endotypes
- Demographics similar; modest but significant differences in anti-dsDNA and complement; no SLEDAI differences
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Subsets of Patients With Lupus Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib. Arthritis Rheumatol. Published 7 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →